Advanced search
Publication Cover
Expert Review of Cardiovascular Therapy Volume 11, 2013 - Issue 12
Submit an article Journal homepage
185
Views
2
CrossRef citations to date
0
Altmetric
Drug Profile

Searching the place of pitavastatin in the current treatment of patients with dyslipidemia

Vivencio BarriosCardiology department. Hospital Ramón y Cajal, Madrid, SpainCorrespondence[email protected]
,
Carlos EscobarCardiology department. Hospital La Paz, Madrid, Spain
&
José L ZamoranoCardiology department. Hospital Ramón y Cajal, Madrid, Spain
Pages 1597-1612 | Published online: 10 Jan 2014

References

  • Reiner Z, Catapano AL, De Backer G et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur. Heart J. 32(14), 1769–1818 (2011).
  • Perk J, De Backer G, Gohlke H et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur. Heart J. 33(13), 1635–1701 (2012).
  • Grau M, Elosua R, Cabrera de León A et al. Cardiovascular risk factors in Spain in the first decade of the 21st Century, a pooled analysis with individual data from 11 population-based studies: the DARIOS study. Rev. Esp. Cardiol. 64(4), 295–304 (2011).
  • Barrios V, Martinez M, Tomas JP et al. Clinical profile of a hypercholesterolemic Spanish population and differences between genders. LIPYCARE study. Hipertensión 21(8), 395–402 (2004).
  • Barrios V, Escobar C, Calderón A et al. Blood pressure and lipid goal attainment in the hypertensive population in the primary care setting in Spain. J. Clin. Hypertens. (Greenwich). 9(5), 324–329 (2007).
  • Barrios V, Escobar C, Bertomeu V, Murga N, de Pablo C, Calderón A. Risk factor control in the hypertensive patients with chronic ischemic heart disease attended in cardiologic outpatient clinics. The CINHTIA study. Rev. Clin. Esp. 208(8), 400–404 (2008).
  • Flores-Mateo G, Grau M, O'Flaherty M et al. Analyzing the coronary heart disease mortality decline in a Mediterranean population: Spain 1988–2005. Rev. Esp. Cardiol. 64(11), 988–996 (2011).
  • Wijeysundera HC, Machado M, Farahati F et al. Association of temporal trends in risk factors and treatment uptake with coronary heart disease mortality, 1994–2005. JAMA 303(18), 1841–1847 (2010).
  • Mancia G, Fagard R, Narkiewicz k et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 31(7), 1281–1357 (2013).
  • American Diabetes Association. Standards of medical care in diabetes--2013. Diabetes Care 36 ( Suppl. 1), S11–66 (2013).
  • Hsia J, MacFadyen JG, Monyak J, Ridker PM. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). J. Am. Coll. Cardiol. 57(16), 1666–1675 (2011).
  • Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U; EUROASPIRE Study Group. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 373(9667), 929–940 (2009).
  • Alvarez-Sala LA, Suárez C, Mantilla T et al. Grupo PREVENCAT. PREVENCAT study: control of cardiovascular risk in primary care. Med. Clin. (Barc). 124(11), 406–410 (2005).
  • Banegas JR, López-García E, Dallongeville J et al. Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. Eur. Heart J. 32(17), 2143–2152 (2011)
  • Escobar C, Echarri R, Barrios V. Relative safety profiles of high dose statin regimens. Vasc. Health Risk Manag. 4(3), 525–533 (2008).
  • LIVALO [prescribing information]. Kowa Pharmaceuticals America, Inc, Montgomery, AL (2012).
  • Catapano AL. Pitavastatin-pharmacological profile from early phase studies. Atheroscler. Suppl. 11(3), 3–7 (2010).
  • Yee LL, Wright EA. Pitavastatin calcium: clinical review of a new antihyperlipidemic medication. Clin. Ther. 33(8), 1023–1042 (2011).
  • Teramoto T, Shimano H, Yokote K, Urashima M. New evidence on pitavastatin: efficacy and safety in clinical studies. Expert Opin. Pharmacother. 11(5), 817–828 (2010).
  • Ose L. Pitavastatin: a distinctive lipid-lowering drug. Clin. Lipidol. 5(4), 309–323 (2010).
  • Saito Y. Critical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goals. Vasc. Health Risk Manag. 5, 921–936 (2009).
  • Ose L. Pitavastatin: finding its place in therapy. Ther. Adv. Chronic. Dis. 2(2), 101–17 (2011).
  • Chen Y, Zhang W, Huang WH et al. Effect of a single-dose rifampin on the pharmacokinetics of pitavastatin in healthy volunteers. Eur. J. Clin. Pharmacol. Jul 7. [ Epub ahead of print] (2013)
  • Chauvin B, Drouot S, Barrail-Tran A, Taburet AM. Drug-drug interactions between HMG-C oA reductase inhibitors (statins) and antiviral protease inhibitors. Clin. Pharmacokinet. 52(10), 815–831 (2013)
  • Zhu J, Song M, Tan HY et al. Effect of pitavastatin in different SLCO1B1 backgrounds on repaglinide pharmacokinetics and pharmacodynamics in healthy Chinese males. Pak. J. Pharm. Sci. 26(3), 577–584 (2013).
  • Zhou Q, Chen QX, Ruan ZR, Yuan H, Xu HM, Zeng S. CYP2C9*3(1075A > C), ABCB1 and SLCO1B1 genetic polymorphisms and gender are determinants of inter-subject variability in pitavastatin pharmacokinetics. Pharmazie 68(3), 187–194 (2013).
  • Hu M, Mak VW, Yin OQ, Chu TT, Tomlinson B. Effects of grapefruit juice and SLCO1B1 388A>G polymorphism on the pharmacokinetics of pitavastatin. Drug Metab. Pharmacokinet. 28(2), 104–108 (2013)
  • Morgan RE, Campbell SE, Suehira K, Sponseller CA, Yu CY, Medlock MM. Effects of steady-state lopinavir/ritonavir on the pharmacokinetics of pitavastatin in healthy adult volunteers. J. Acquir. Immune. Defic. Syndr. 60(2), 158–164 (2012).
  • Jung JA, Noh YH, Jin S et al. Pharmacokinetic interaction between pitavastatin and valsartan: a randomized, open-labeled crossover study in healthy male Korean volunteers. Clin. Ther. 34(4), 958–965 (2012).
  • Yu CY, Campbell SE, Zhu B et al. Effect of pitavastatin vs. rosuvastatin on international normalized ratio in healthy volunteers on steady-state warfarin. Curr. Med. Res. Opin 28(2), 187–194 (2012).
  • Catapano AL. Statin-induced myotoxicity: pharmacokinetic differences among statins and the risk of rhabdomyolysis, with particular reference to pitavastatin. Curr. Vasc. Pharmacol. 10(2), 257–267 (2012).
  • Corsini A, Ceska R. Drug-drug interactions with statins: will pitavastatin overcome the statins' Achilles' heel? Curr. Med. Res. Opin. 27(8), 1551–1562 (2011).
  • Inagaki Y, Hunt T, Arana B, Gosho M, Morgan R. Drug-drug interaction study to assess the effects of multiple-dose pitavastatin on steady-state warfarin in healthy adult volunteers. J. Clin. Pharmacol. 51(9), 1302–1309 (2011).
  • Neuvonen PJ. Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics. Curr. Opin Investig. Drugs 11(3), 323–332 (2010).
  • Shitara Y, Hirano M, Sato H, Sugiyama Y. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug–drug interaction between cerivastatin and gemfibrozil. J. Pharmacol. Exp. Ther. 311(1), 228–236 (2004).
  • Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin. Pharmacol. Ther. 80(6), 565–581 (2006).
  • Warrington S, Nagakawa S, Hounslow N. Comparison of the pharmacokinetics of pitavastatin by formulation and ethnic group: an open-label, single-dose, two-way crossover pharmacokinetic study in healthy Caucasian and Japanese men. Clin. Drug. Investig. 31(10), 735–743 (2011).
  • Morgan RE, Campbell SE, Yu CY, Sponseller CA, Muster HA. Comparison of the safety, tolerability, and pharmacokinetic profile of a single oral dose of pitavastatin 4 mg in adult subjects with severe renal impairment not on hemodialysis versus healthy adult subjects. J. Cardiovasc. Pharmacol. 60(1), 42–48 (2012).
  • Saito Y, Yamada N, Teramoto T et al. Clinical efficacy of pitavastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in patients with hyperlipidemia. Dose-finding study using the double-blind, three-group parallel comparison. Arzneimittelforschung 52(4), 251–255 (2002).
  • Mao Y, Yu JM, Zhan YQ et al. Safety and efficacy of pitavastatin in patients with hypercholesterolemia: a multicenter study. Zhonghua. Yi. Xue. Za. Zhi. 92(14), 968–973 (2012).
  • Park S, Kang HJ, Rim SJ et al. A randomized, open-label study to evaluate the efficacy and safety of pitavastatin compared with simvastatin in Korean patients with hypercholesterolemia. Clin. Ther. 27(7), 1074–1082 (2005).
  • Ose L, Budinski D, Hounslow N, Arneson V. Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia. Curr. Med. Res. Opin 25(11), 2755–2764 (2009).
  • Eriksson M, Budinski D, Hounslow N. Comparative efficacy of pitavastatin and simvastatin in high-risk patients: a randomized controlled trial. Adv. Ther. 28(9), 811–823 (2011).
  • Saito Y, Yamada N, Teramoto T et al. A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. Atherosclerosis 162(2), 373–379 (2002).
  • Lee SH, Chung N, Kwan J et al. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia. Clin. Ther. 29(11), 2365–2373 (2007).
  • Yokote K, Bujo H, Hanaoka H et al. Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients: collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study). Atherosclerosis 201(2), 345–352 (2008).
  • Budinski D, Arneson V, Hounslow N, Gratsiansky N. Pitavastatin compared with atorvastatin in primary hypercholesterolemia or combined dyslipidemia. Clin. Lipidol. 4(3), 291–302 (2009).
  • Sansanayudh N, Wongwiwatthananukit S, Putwai P, Dhumma-Upakorn R. Comparative efficacy and safety of low-dose pitavastatin versus atorvastatin in patients with hypercholesterolemia. Ann. Pharmacother. 44(3), 415–423 (2010).
  • Poolsup N, Suksomboon N, Wongyaowarat K, Rungkanchananon B, Niyomrat P, Kongsuwan S. Meta-analysis of the comparative efficacy and safety of pitavastatin and atorvastatin in patients with dyslipidaemia. J. Clin. Pharm. Ther. 37(2), 166–172 (2012).
  • Saku K, Zhang B, Noda K; PATROL Trial Investigators. Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL trial. Circ. J. 75(6), 1493–1505 (2011).
  • Ose L, Budinski D, Hounslow N, Arneson V. Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia. Atherosclerosis 210(1), 202–208 (2010).
  • Kurihara Y, Douzono T, Kawakita K, Nagasaka Y. A large-scale, long-term, prospective post-marketing surveillance of pitavastatin (LIVALO® Tablet)-LIVALO Effectiveness and safety (LIVES) Study. Jpn Pharmacol. Ther. 36(8), 709–731 (2008).
  • Teramoto T, Urashima M, Shimano H et al. A large-scale study on cardio-cerebrovascular events during pitavastatin (LIVALO tablet) therapy in Japanese patients with hypercholesterolemia: LIVES 5-year extension study. Jpn. Pharmacol. Ther. 39(9), 789–803 (2011).
  • Teramoto T, Shimano H, Yokote K, Urashima M. Effects of pitavastatin (LIVALO Tablet) on high density lipoprotein cholesterol (HDL-C) in hypercholesterolemia. J. Atheroscler. Thromb. 16(5), 654–661 (2009).
  • Teramoto T. Pitavastatin: clinical effects from the LIVES Study. Atheroscler. Suppl. 12(3), 285–288 (2011).
  • Yokote K, Shimano H, Urashima M, Teramoto T. Efficacy and safety of pitavastatin in Japanese patients with hypercholesterolemia: LIVES study and subanalysis. Expert Rev. Cardiovasc. Ther. 9(5), 555–562 (2011).
  • Betteridge J. Pitavastatin- results from phase III & IV. Atheroscler. Suppl. 11(3), 8–14 (2010).
  • Teramoto T. The clinical impact of pitavastatin: comparative studies with other statins on LDL-C and HDL-C. Expert Opin. Pharmacother. 13(6), 859–865 (2012).
  • Sasaki J, Ikeda Y, Kuribayashi T et al. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance. Clin. Ther. 30(6), 1089–1101 (2008).
  • Eriksson M, Budinski D, Hounslow N. Long-term efficacy of pitavastatin versus simvastatin. Adv. Ther. 28(9), 799–810 (2011).
  • Sattar N, Preiss D, Murray HM et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 375(9716), 735–742 (2010).
  • Barrios V, Escobar C. Rosuvastatin and diabetes: when the evidences talk. Cardiovasc. Hematol. Agents Med. Chem. 11(2), 115–124 (2013).
  • Naci H, Brugts J, Ades T. Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials. Circ. Cardiovasc. Qual. Outcomes 6(4), 390–399 (2013).
  • Kawai Y, Sato-Ishida R, Motoyama A, Kajinami K. Place of pitavastatin in the statin armamentarium: promising evidence for a role in diabetes mellitus. Drug. Des. Devel. Ther. 5, 283–297 (2011).
  • Sasaki J, Iwashita M, Kono S. Statins: Beneficial or adverse for glucose metabolism. J. Atheroscler. Thromb. 13(3), 123–129 (2006).
  • Kawai T, Tokui M, Funae O et al. Efficacy of Pitavastatin, a new HMG-CoA reductase inhibitor, on lipid and glucose metabolism in patients with type 2 diabetes. Diabetes Care 28(12), 2980–2981 (2005).
  • Yokote K, Saito Y; CHIBA. Influence of statins on glucose tolerance in patients with type 2 diabetes mellitus: subanalysis of the collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study). J. Atheroscler. Thromb. 16(3), 297–298 (2009).
  • Yamakawa T, Takano T, Tanaka S, Kadonosono K, Terauchi Y. Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus. J. Atheroscler. Thromb. 15(5), 269–275 (2008).
  • Gumprecht J, Gosho M, Budinski D, Hounslow N. Comparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20–40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia. Diabetes. Obes. Metab. 13(11), 1047–1055 (2011).
  • Mao Y, Yu JM, Zhang F et al. The effect of pitavastatin on blood glucose and its efficacy in diabetic patients with hypercholesterolemia. Zhonghua. Nei. Ke. Za. Zhi. 51(7), 508–512 (2012).
  • Shimabukuro M, Higa M, Tanaka H, Shimabukuro T, Yamakawa K, Masuzaki H. Distinct effects of pitavastatin and atorvastatin on lipoprotein subclasses in patients with Type 2 diabetes mellitus. Diabet. Med. 28(7), 856–864 (2011).
  • Keane WF, Lyle PA. Kidney disease and cardiovascular disease: implications of dyslipidemia. Cardiol. Clin. 23(3), 363–372 (2005).
  • Harper CR, Jacobson TA. Managing dyslipidemia in chronic kidney disease. J. Am. Coll. Cardiol. 51(25), 2375–2384 (2008).
  • Barrios V, Escobar C. Rosuvastatin and cardiovascular continuum when time is important. J. Am. Coll. Cardiol. 55(15), 1645–1646 (2010).
  • Kimura K, Shimano H, Yokote K, Urashima M, Teramoto T. Effects of pitavastatin (LIVALO tablet) on the estimated glomerular filtration rate (eGFR) in hypercholesterolemic patients with chronic kidney disease. Sub-analysis of the LIVALO Effectiveness and Safety (LIVES) Study. J. Atheroscler. Thromb. 17(6), 601–609 (2010).
  • Kakuda H, Kanasaki K, Koya D, Takekoshi N. The administration of pitavastatin augments creatinine clearance associated with reduction in oxidative stress parameters: acute and early effects. Clin. Exp. Nephrol. 17(2), 240–247 (2013).
  • Kimura S, Inoguchi T, Yokomizo H, Maeda Y, Sonoda N, Takayanagi R. Randomized comparison of pitavastatin and pravastatin treatment on the reduction of urinary albumin in patients with type 2 diabetic nephropathy. Diabetes. Obes. Metab. 14(7), 666–669 (2012).
  • Yagi S, Akaike M, Aihara K et al. Effect of low-dose (1 mg/day) pitavastatin on left ventricular diastolic function and albuminuria in patients with hyperlipidemia. Am. J. Cardiol. 107(11), 1644–1649 (2011).
  • Nakamura T, Sugaya T, Kawagoe Y, Suzuki T, Inoue T, Node K. Effect of pitavastatin on urinary liver-type fatty-acid-binding protein in patients with nondiabetic mild chronic kidney disease. Am. J. Nephrol. 26(1), 82–86 (2006).
  • Nakamura T, Sugaya T, Kawagoe Y, Ueda Y, Osada S, Koide H. Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy. Diabetes Care 28(11), 2728–2732 (2005).
  • Tamura Y, Murayama T, Minami M, Yokode M, Arai H. Differential effect of statins on diabetic nephropathy in db/db mice. Int. J. Mol. Med. 28(5), 683–687 (2011).
  • Davignon J. Pleiotropic effects of pitavastatin. Br. J. Clin. Pharmacol. 73(4), 518–535 (2012).
  • da Silva PM. Are all statins the same? Focus on the efficacy and tolerability of pitavastatin. Am. J. Cardiovasc. Drugs 11(2), 93–107 (2011).
  • Glynn RJ, Koenig W, Nordestgaard BG, Shepherd J, Ridker PM. Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Ann. Intern. Med. 152(8), 488–496 (2010).
  • Stender S, Budinski D, Gosho M, Hounslow N. Pitavastatin shows greater lipid-lowering efficacy over 12 weeks than pravastatin in elderly patients with primary hypercholesterolaemia or combined (mixed) dyslipidaemia. Eur. J. Prev. Cardiol. 20(1), 40–53 (2013).
  • Stender S, Budinski D, Hounslow N. Pitavastatin demonstrates long-term efficacy, safety and tolerability in elderly patients with primary hypercholesterolaemia or combined (mixed) dyslipidaemia. Eur. J. Prev. Cardiol. 20(1), 29–39 (2013).
  • Nicholls SJ, Ballantyne CM, Barter PJ et al. Effect of two intensive statin regimens on progression of coronary disease. N. Engl. J. Med. 365(22), 2078–2087 (2011).
  • LaRosa JC, Grundy SM, Waters DD et al.; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med. 352(14), 1425–1435 (2005).
  • Toi T, Taguchi I, Yoneda S et al. Early effect of lipid-lowering therapy with pitavastatin on regression of coronary atherosclerotic plaque. Comparison with atorvastatin. Circ. J. 73(8), 1466–1472 (2009).
  • Hiro T, Kimura T, Morimoto T et al.; JAPAN-ACS Investigators. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study). J. Am. Coll. Cardiol. 54(4), 293–302 (2009).
  • Arai H, Hiro T, Kimura T et al. More intensive lipid lowering is associated with regression of coronary atherosclerosis in diabetic patients with acute coronary syndrome—sub-analysis of JAPAN-ACS study. J. Atheroscler. Thromb. 17(10), 1096–1107 (2010).
  • Hibi K, Kimura T, Kimura K et al.; JAPAN-ACS Investigators. Clinically evident polyvascular disease and regression of coronary atherosclerosis after intensive statin therapy in patients with acute coronary syndrome: serial intravascular ultrasound from the Japanese assessment of pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS) trial. Atherosclerosis 219(2), 743–749 (2011).
  • Hong YJ, Jeong MH, Ahn Y et al.; LAMIS investigators. Effect of pitavastatin treatment on changes of plaque volume and composition according to the reduction of high-sensitivity C-reactive protein levels. J. Cardiol. 60(4), 277–282 (2012).
  • Maruyama T, Takada M, Nishibori Y et al. Comparison of preventive effect on cardiovascular events with different statins. the CIRCLE study. Circ. J. 75(8), 1951–1959 (2011).
  • Natsuaki M, Furukawa Y, Morimoto T et al.; CREDO-Kyoto PCI/CABG registry cohort-2 investigators. Intensity of statin therapy, achieved low-density lipoprotein cholesterol levels and cardiovascular outcomes in Japanese patients after coronary revascularization. Perspectives from the CREDO-Kyoto registry cohort-2. Circ. J. 76(6), 1369–1379 (2012).
  • Suh SY, Rha SW, Ahn TH et al.; LAMIS Investigators. Long-term safety and efficacy of Pitavastatin in patients with acute myocardial infarction (from the Livalo Acute Myocardial Infarction Study [LAMIS]). Am. J. Cardiol. 108(11), 1530–1535 (2011).
  • Ibuki C, Seino Y, Otsuka T et al. Switching to Pitavastatin in Statin-Treated Low HDL-C Patients Further Improves the Lipid Profile and Attenuates Minute Myocardial Damage. J. Clin. Med. Res. 4(6), 385–392 (2012).
  • Tsukie N, Nakano K, Matoba T et al. Pitavastatin-incorporated nanoparticle-eluting stents attenuate in-stent stenosis without delayed endothelial healing effects in a porcine coronary artery model. J. Atheroscler. Thromb. 20(1), 32–45 (2013).
  • Koshiyama H, Taniguchi A, Tanaka K et al. Effects of pitavastatin on lipid profiles and high-sensitivity CRP in Japanese subjects with hypercholesterolemia: Kansai Investigation of Statin for Hyperlipidemic Intervention in Metabolism and Endocrinology (KISHIMEN) investigators. J. Atheroscler. Thromb. 15(6), 345–350 (2008).
  • Mao Y, Yu JM, Zhan YQ et al. Effect and risk factors of pitavastatin on high sensitivity C-reactive protein in patients with hypercholesterolemia: a multilevel models analysis. Zhonghua. Yi Xue. Za. Zhi. 92(24), 1681–1685 (2012).
  • Matsubara T, Naruse K, Arakawa T et al. Impact of pitavastatin on high-sensitivity C-reactive protein and adiponectin in hypercholesterolemic patients with the metabolic syndrome: the PREMIUM Study. J. Cardiol. 60(5), 389–394 (2012).
  • Ridker PM, Macfadyen JG, Nordestgaard BG et al. Rosuvastatin for primary prevention among individuals with elevated high-sensitivity c-reactive protein and 5% to 10% and 10% to 20% 10-year risk. Implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial for “intermediate risk”. Circ. Cardiovasc. Qual. Outcomes 3(5), 447–452 (2010).
  • Kurogi K, Sugiyama S, Sakamoto K et al.; COMPACT-CAD Investigators. Comparison of pitavastatin with atorvastatin in increasing HDL-cholesterol and adiponectin in patients with dyslipidemia and coronary artery disease: the COMPACT-CAD study. J. Cardiol. 62(2), 87–94 (2013)
  • Nomura S, Taniura T, Shouzu A et al. Effects of pitavastatin on plasminogen activator inhibitor-1 in hyperlipidemic patients. Int. J. Gen. Med. 5, 535–540 (2012).
  • Ansari JA, Bhandari U, Haque SE, Pillai KK. Enhancement of antioxidant defense mechanism by pitavastatin and rosuvastatin on obesity-induced oxidative stress in Wistar rats. Toxicol. Mech. Methods. 22(1), 67–73 (2012).
  • Yoshida H, Shoda T, Yanai H et al. Effects of pitavastatin and atorvastatin on lipoprotein oxidation biomarkers in patients with dyslipidemia. Atherosclerosis 226(1), 161–164 (2013).
  • Miyamoto-Sasaki M, Yasuda T, Monguchi T et al. Pitavastatin increases HDL particles functionally preserved with cholesterol efflux capacity and antioxidative actions in dyslipidemic patients. J. Atheroscler. Thromb. (2013) ( Epub ahead of print).
  • Sakabe K, Fukuda N, Fukuda Y et al. Comparisons of short-and intermediate-term effects of pitavastatin versus atorvastatin on lipid profiles, fibrinolytic parameter, and endothelial function. Int. J. Cardiol. 201(1), 136–138 (2008).
  • Yan HM, Zhao J, Ma DZ et al. The effect of pitavastatin calcium on endothelial dysfunction induced by hypercholesterolemia. Expert Opin Pharmacother. 12(10), 1463–1471 (2011).
  • Kono Y, Fukuda S, Shimada K et al. Very rapid effect of pitavastatin on microvascular function in comparison to rosuvastatin: reactive hyperemia peripheral arterial tonometric study. Drug Des. Devel. Ther. 7, 369–374 (2013).
  • Kikuchi R, Takeshita K, Uchida Y et al. Pitavastatin-induced angiogenesis and arteriogenesis is mediated by Notch1 in a murine hind limb ischemia model without induction of VEGF. Lab. Invest. 91(5), 691–703 (2011).
  • Mizuguchi Y, Oishi Y, Miyoshi H et al. Impact of statin therapy on left ventricular function and carotid arterial stiffness in patients with hypercholesterolemia. Circ. J. 72(4), 538–544 (2008).
  • Nakamura T, Obata JE, Kitta Y et al. Rapid stabilization of vulnerable carotid plaque within 1 month of pitavastatin treatment in patients with acute coronary syndrome. J. Cardiovasc. Pharmacol. 51(4), 365–371 (2008).
  • Ikeda K, Takahashi T, Yamada H et al. Effect of intensive statin therapy on regression of carotid intima-media thickness in patients with subclinical carotid atherosclerosis (a prospective, randomized trial: PEACE (Pitavastatin Evaluation of Atherosclerosis Regression by Intensive Cholesterol-lowering Therapy) study). Eur. J. Prev. Cardiol. doi:10.1177/2047487312451539 (2012) ( Epub ahead of print).
  • Ono K, Kawasaki M, Tanaka R et al. Integrated backscatter and intima media thickness of the thoracic aorta evaluated by transesophageal echocardiography in hypercholesterolemic patients: effect of pitavastatin therapy. Ultrasound. Med. Biol. 35(2), 193–200 (2009).
  • Tajiri K, Shimojo N, Sakai S et al. Pitavastatin Regulates Helper T-C ell Differentiation and Ameliorates Autoimmune Myocarditis in Mice. Cardiovasc. Drugs Ther. doi:10.1007/s10557–013-6464-y (2013) ( Epub ahead of print).
  • Warita S, Kawasaki M, Tanaka R et al. Effects of pitavastatin on cardiac structure and function and on prevention of atrial fibrillation in elderly hypertensive patients: a prospective study of 2-years' follow-up. Circ. J. 76(12), 2755–2762 (2012).
  • Han KH, Rha SW, Kang HJ et al. Evaluation of short-term safety and efficacy of HMG-CoA reductase inhibitors in hypercholesterolemic patients with elevated serum alanine transaminase concentrations: PITCH study (PITavastatin versus atorvastatin to evaluate the effect on patients with hypercholesterolemia and mild to moderate hepatic damage). J. Clin. Lipidol. 6(4), 340–351 (2012).
  • Kamada Y, Kiso S, Yoshida Y et al. Pitavastatin ameliorated the progression of steatohepatitis in ovariectomized mice fed a high fat and high cholesterol diet. Hepatol. Res. 43(4), 401–412 (2013).
  • Miyaki T, Nojiri S, Shinkai N et al. Pitavastatin inhibits hepatic steatosis and fibrosis in non-alcoholic steatohepatitis model rats. Hepatol. Res. 41(4), 375–385 (2011).
  • Kohjima M, Enjoji M, Yoshimoto T et al. Add-on therapy of pitavastatin and eicosapentaenoic acid improves outcome of peginterferon plus ribavirin treatment for chronic hepatitis C. J. Med. Virol. 85(2), 250–260 (2013).
  • Kurata T, Miyazaki K, Morimoto N et al. Atorvastatin and pitavastatin reduce oxidative stress and improve IR/LDL-R signals in Alzheimer's disease. Neurol. Res. 35(2), 193–205 (2013).
  • Kurata T, Kawai H, Miyazaki K et al. Statins have therapeutic potential for the treatment of Alzheimer's disease, likely via protection of the neurovascular unit in the AD brain. J. Neurol. Sci. 322(1–2), 59–63 (2012).
  • Kurata T, Miyazaki K, Kozuki M et al. Atorvastatin and pitavastatin reduce senile plaques and inflammatory responses in a mouse model of Alzheimer's disease. Neurol. Res. 34(6), 601–610 (2012).
  • Colivicchi F, Tubaro M, Santini M. Clinical implications of switching from intensive to moderate statin therapy after acute coronary syndromes. Int. J. Cardiol. 152(1), 56–60 (2011).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.